drugset / Trial / NCT00757809

Study Evaluating The Tolerability Of Multiple Doses Of HKI-272

NCT00757809

Phase 1 Completed 50 enrolled Puma Biotechnology, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to investigate the occurence of diarrhea after either once daily or twice daily dosing for 14 days.

Timeline

Start
2008-10
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Neratinib Small molecule 120 mg
Subject Neratinib Small molecule 240 mg

Indications

No indication recorded.